echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third batch of countries are getting closer: 4 major pain points of enterprises, how to deal with it?

    The third batch of countries are getting closer: 4 major pain points of enterprises, how to deal with it?

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medicine Network Monthly News, the third batch of national volume procurement "mountain rain want to wind full of buildings." The new news shows the follow-up progress or in accordance with the following timetable: the Shanghai Joint Acquisition Office statistics of the amount of products reported to the State Health Insurance Bureau; Some provinces and cities have carried out or ended the corresponding reporting work, but still some provinces have not reported the amount of information so far statistics show that Ningxia, Hunan, Hubei, Tibet, Beijing, Guangdong and other provinces (municipalities and autonomous regions) to carry out the third batch of drug reporting workWhat is the future strategy of pharmaceutical companies? How should operational challenges be resolved? What are the major impacts of collection on the pharmaceutical industry? Enterprise "pain point", is carrying out consistency evaluation of some of the enterprise risk increases, for example, for the company is carrying out the consistency evaluation of metformin products, the future of the product can only be left to godBecause the review wants to enter the future catalog and negotiate its competitive pressure is very largeHowever, the review to exit the hospital market into the retail market will be with the original research manufacturers in a fierce competitionBecause the original research manufacturers regardless of brand awareness or patient medication habits will be the winner, non-selected products in the hospital will no longer be favored in the recent National Health Insurance Bureau, the Ministry of Finance "on the national organization of drug centralized procurement work of the guidance on the retention of health insurance balance funds" Health insurance issued on the hospital to implement the compensation program of the amount of procurement of this opinion on the third batch of national collection has a very large impactHospital compensation mechanism and belt procurement use direct linkage using the belt purchase products the more hospital report and dosage the higher the hospital can get the more compensationAccording to the formula, medical institutions need to reduce the amount of non-successful products to obtain as much balance as possibleThis is the hospital to minimize the use of non-secondary products of great motivationNon-selected products in the hospital will no longer be favored living space or will be further squeezed not to choose almost equal to perishmentThe policy provisions on offline procurement and defeated drugs are not allowed in principle by the provinces (municipalities) or the overall setting of standards at the same time the proportion of offline procurement amount into the hospital's large assessment indicatorsThe aim is to prevent hospital "dark box" operations to ensure that all drug online procurement prevents hospitals from switching to offline purchases of failed drugs" Growth-oriented enterprises or small pharmaceutical enterprises transformation of the "life and death" consideration of the hospital market has become the mainstream market of the national purchase of its policies have been large enterprises to show the platform growth enterprises or small pharmaceutical enterprises because of the cost, brand, marketing and other constraints are difficult to compete with large enterprises so the hospital market to retail or primary healthcare market will be the key to extend the life cycle of these products in the futureAnd to open up new areas also need periodic all-round investment without transformation difficult to survive the transformation can not be concludedAccording to Beijing Asahi Boyuan management consulting analysts combed the first two batches of catalogs and forecast the third batch of catalog comparison and industry impact as shown in the tableThe strategy of selecting the variety layout of domestic enterprises: from the previous "big and wide" to "fine and fine" to concentrate on the key varieties, from raw materials and other costs, drug alert system and other quality management aspects to strive to achieve excellenceDosage innovation or research and development innovation: the deepening of the collection policy to a certain extent has accelerated the domestic high-quality pharmaceutical enterprises to the characteristics of the formulation and innovative drugs transformation of the pace Product review: collection policy will only further further promote so that the strength of pharmaceutical companies to increase consistency evaluation input is king Road Acapo sugar for the first time collection of Bayer and Green Leaf Pharmaceuticals to share the market and the existing three over-rated manufacturers because of its huge market size of over 100 million attracted more pharmaceutical companies to invest in consistency evaluation of the current stone pharmaceutical group Oyi Pharmaceuticals, Zhejiang Haizheng Pharmaceuticals and other domestic pharmaceutical companies (a total acceptance number) of generic listing applications are under review and approval By then, the review company will be expected to grab a "cake" at the next Acapo sugar collection For the hospital channels: do a good job of the hospital has won the product quality assurance, supply guarantee, service guarantee can finally reach the sales guarantee In short, through the work to promote to ensure sales? Pharmacy channels: drugstores in prescription drug sales have a great deal of convenience and service advantages, but because of the patient's drug habits and the brand value of the original research products patients will not easily replace other manufacturers of varieties of original research products will take down the plan to purchase most of the market will also become a sought-after drugstore Therefore, domestic enterprises to seize the front of foreign enterprises early with the chain industry cooperation in order to obtain priority Foreign companies accept price reduction is a must-see, do not reduce prices will eventually be out: the third batch of volume procurement involving a total of foreign enterprises involved in the largest number of original research varieties are Mersadon and Pfizer each have a variety Mersatom has finasteride, relying on kaxix, ground chlorate he a constant release dosage form, Monruster and Monrust chewing tablets Pfizer has shetrein, seratib, tofatib, linamine an oral permanent release agent type and non-medicalized cynta The expansion of the new market after the exit: accept the reality of the reality Now is not the original research products have the advantage of the era of the future turn where should be considered in advance? Where to turn? Other non-public medical or pharmacy channels? Further comprehensive thinking is needed in terms of category characteristics and existing team resources Pharmacies follow the trend to follow the national collection Only participating in the collection of products at competitive prices can retain customers Strengthen the depth of cooperation with upstream mining products industrial enterprises The slow-disease management of industrial enterprises participating in the product brand can enhance the viscosity of the store by providing special marketing activities by industrial enterprises by the industrial enterprises Digging deep into the potential of health products around chronic products to boost profits for pharmacies Through health food, Chinese medicine tablets and other health products to help chronic ally patients to adjust the body to enhance the professional service capacity and sales scale of pharmacies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.